LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $15.00

LifeStance Health Group (NASDAQ:LFST) had its target price upped by Barclays from $13.00 to $15.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 18.86% from the stock’s previous close.

A number of other equities analysts also recently issued reports on LFST. JPMorgan Chase & Co. increased their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. The Goldman Sachs Group assumed coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price on the stock. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. KeyCorp upped their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, BTIG Research raised their price objective on LifeStance Health Group from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.88.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $12.62 on Thursday. The firm has a market capitalization of $4.89 billion, a price-to-earnings ratio of 97.08 and a beta of 1.22. The stock has a fifty day moving average of $11.60 and a 200 day moving average of $8.93. LifeStance Health Group has a 52 week low of $4.77 and a 52 week high of $13.15. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same period in the previous year, the firm earned ($0.01) EPS. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. As a group, research analysts expect that LifeStance Health Group will post 0.16 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the sale, the insider directly owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Lisa Miller sold 47,912 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the sale, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 14,671,917 shares of company stock valued at $155,493,415. 3.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of institutional investors have recently modified their holdings of the stock. Assetmark Inc. increased its holdings in shares of LifeStance Health Group by 17.0% during the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after acquiring an additional 1,367 shares in the last quarter. Allworth Financial LP boosted its stake in LifeStance Health Group by 7.7% in the 2nd quarter. Allworth Financial LP now owns 26,532 shares of the company’s stock worth $284,000 after purchasing an additional 1,889 shares in the last quarter. California State Teachers Retirement System grew its position in LifeStance Health Group by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after purchasing an additional 1,966 shares during the last quarter. Vident Advisory LLC grew its position in LifeStance Health Group by 12.7% during the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the last quarter. Finally, Xponance LLC grew its position in LifeStance Health Group by 26.4% during the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after purchasing an additional 2,745 shares during the last quarter. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.